Healthcare
Live Price
Offline$4.32
-0.69% today
1Y Change
+430.95%
Window
Jun 23, 2025 → Jun 15, 2026
Coverage: 247 bars · Jun 23, 2025 → Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Prelude Therapeutics Incorporated (PRLD) is a Healthcare stock with a market cap of $260.00M and listed on NASDAQ. The stock last traded around $4.32 and up 431.0% across the available one-year price window (Jun 23, 2025 → Jun 15, 2026). Baseline metrics include revenue growth of +73.4%, EPS growth of +23.2%, a dividend yield of 0.0%. What stands out right now is revenue +73.4%, EPS +23.2%, free cash flow +45.6% with operating margin -861.3% and ROIC -114.8%. Valuation already assumes a fairly strong business story at price/sales 21.6. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines PRLD price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PRLD
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
PRLD Max Drawdown
-70.10%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for PRLD and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$111.7M
+3.2% YoY
Free Cash Flow
-$85.9M
+1.0% YoY
Revenue Growth
+73.4%
EPS Growth
+23.2%
Gross Margin
93.1%
Net Margin
-819.6%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 12M | 7M | 0 | 0 | 0 |
| Gross Profit | 10M | 7M | 0 | 0 | 0 |
| Operating Income | -105M | -140M | -132M | -124M | -114M |
| EBITDA | -103M | -138M | -131M | -122M | -113M |
| Net Income | -99M | -127M | -122M | -115M | -112M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 35M | 12M | 25M | 31M | 32M |
| Total Assets | 141M | 176M | 278M | 221M | 305M |
| Total Liabilities | 73M | 44M | 41M | 25M | 19M |
| Shareholder Equity | 69M | 131M | 237M | 195M | 286M |
| Total Debt | 18M | 18M | 17M | 2M | 2M |
| Net Debt | -17M | 6M | -8M | -29M | -30M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
84M
+0.2% YoY
Capital Expenditures
2M
+23.1% YoY
Free Cash Flow
86M
+1.0% YoY
Key ratios
Gross Margin
93.1%
Operating Margin
-861.3%
Net Margin
-819.6%
ROE
-130.0%
Debt / Equity
0.26x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.